DexCom company profile
Company profile
DexCom has 11,000 employees and is headquartered in San Diego, United States.
Its core activity is the design, development and sale of continuous glucose monitoring devices for people with diabetes and for metabolic health management. The range includes the Dexcom G7 and G7 15 Day integrated sensor, the Dexcom G6 system, and the Dexcom ONE+, which is intended to replace fingerstick testing in treatment decisions. The company also offers Stelo, a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin, together with Dexcom Share for remote monitoring and the Dexcom Follow app. Products are marketed directly to endocrinologists, physicians and diabetes educators in the United States and abroad.
In the fiscal year ended December 2025, DexCom reported revenue of 4.7 billion US dollars, up 15.6% from the previous year, and net income of 836.3 million US dollars. The United States accounted for 71.5% of revenue and non-US markets for 28.5%. The company had 11,000 employees, is headquartered in San Diego, California, and was incorporated in 1999.
Company facts
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Headquarters
- 6340 Sequence Drive, 92121, San Diego
- Employees
- 11,000
- Chief executive
- Jacob Leach
- Founded
- 1999
- Fiscal year
- January - December
- Listing
- DXCM · NASDAQ
- Indices
- Nasdaq 100S&P 500
- Currency
- USD
- ISIN
- US2521311074
- Website
- dexcom.com
DexCom and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| DexComDXCM | United States | $31.08B | 11,000 | 24.0% | 32.8 |
| GE HealthCare TechnologiesGEHC | United States | $37.8B | 54,000 | 13.8% | 17.7 |
| SterisSTE | United States | $25.67B | 17,937 | 19.2% | 31.4 |
| Zimmer Biomet HoldingsZBH | United States | $19.53B | 17,000 | 16.7% | 26.1 |
| Edwards LifesciencesEW | United States | $61.61B | 16,000 | 28.8% | 61.6 |
| Boston ScientificBSX | United States | $64.27B | 59,000 | 19.6% | 18.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
